Uccc-Gi-20-02
Posted Date: May 6, 2021
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology, Pancreatic Cancer
- Type of Study: Drug
The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma. Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil, irinotecan and oxaliplatin. Patients will undergo radiation therapy if recommended. Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy
Criteria:
Diagnosis Of Pancreatic Carcinoma Or Adenocarcinoma Confirmed By Tissue, Resectable Or Borderline Resectable Primary Tumor, Ecog 0-1, Adequate Organ And Marrow Function As Defined In Protocol, No Uncontrolled Intercurrent Illness Or Comorbidities That Wo
Keywords:
Pancreatic Cancer, Adenocarcinoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com